JP7224331B2 - 脂肪毒性損傷の低減のための化合物 - Google Patents

脂肪毒性損傷の低減のための化合物 Download PDF

Info

Publication number
JP7224331B2
JP7224331B2 JP2020501125A JP2020501125A JP7224331B2 JP 7224331 B2 JP7224331 B2 JP 7224331B2 JP 2020501125 A JP2020501125 A JP 2020501125A JP 2020501125 A JP2020501125 A JP 2020501125A JP 7224331 B2 JP7224331 B2 JP 7224331B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
compound
subject
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020501125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527138A5 (enExample
JP2020527138A (ja
Inventor
ピー． シング，ヴィジャイ
アナンダン，サンパス－クマー
グリーンマン，ケヴィン
カマル，ジーシャン
Original Assignee
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ filed Critical メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ
Publication of JP2020527138A publication Critical patent/JP2020527138A/ja
Publication of JP2020527138A5 publication Critical patent/JP2020527138A5/ja
Application granted granted Critical
Publication of JP7224331B2 publication Critical patent/JP7224331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
JP2020501125A 2017-07-12 2018-07-12 脂肪毒性損傷の低減のための化合物 Active JP7224331B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531454P 2017-07-12 2017-07-12
US62/531,454 2017-07-12
PCT/US2018/041796 WO2019014434A1 (en) 2017-07-12 2018-07-12 COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS

Publications (3)

Publication Number Publication Date
JP2020527138A JP2020527138A (ja) 2020-09-03
JP2020527138A5 JP2020527138A5 (enExample) 2021-08-12
JP7224331B2 true JP7224331B2 (ja) 2023-02-17

Family

ID=65002124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501125A Active JP7224331B2 (ja) 2017-07-12 2018-07-12 脂肪毒性損傷の低減のための化合物

Country Status (14)

Country Link
US (5) US11339126B2 (enExample)
EP (2) EP3651784B1 (enExample)
JP (1) JP7224331B2 (enExample)
KR (1) KR102679975B1 (enExample)
CN (1) CN111343999B (enExample)
AU (2) AU2018300985B2 (enExample)
BR (1) BR112020000635B1 (enExample)
CA (1) CA3069526A1 (enExample)
DK (1) DK4218753T3 (enExample)
ES (2) ES2934883T3 (enExample)
IL (1) IL271884B2 (enExample)
PL (2) PL4218753T3 (enExample)
SG (1) SG11202000239XA (enExample)
WO (1) WO2019014434A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651784B1 (en) 2017-07-12 2022-09-28 Mayo Foundation for Medical Education and Research Compounds for the reducing lipotoxic damage
AU2022261098A1 (en) * 2021-04-23 2023-10-26 Panafina, Inc. Methods of synthesizing lipstatin derivatives
CN114560887B (zh) * 2022-02-15 2024-01-26 安徽美致诚药业有限公司 一种制备奥利司他的中间体的制备方法
CA3246171A1 (en) * 2022-03-31 2023-10-05 Mayo Foundation For Medical Education And Research METHODS AND MATERIALS FOR THE TREATMENT OF PANCREATIC DISEASES AND DISORDERS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523131A (ja) 2004-02-23 2007-08-16 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング リパーゼ抑制剤としてのアルキルカルバマート置換したβ−ラクトン
US20120289588A1 (en) 2011-04-15 2012-11-15 Vijay Prem Singh Lipase Inhibitors for the Treatment of Pancreatitis and Organ Failure
US20150099800A1 (en) 2012-05-24 2015-04-09 Northeastern University Novel lipase inhibitors, reporter substrates and uses thereof
WO2016102541A1 (en) 2014-12-22 2016-06-30 Université Libre de Bruxelles Composition comprising vancomycin and orlistat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxetanones a process for their manufacture and pharmaceutical compositions containing them
FR2754827B1 (fr) 1996-10-17 1998-12-24 Biocem Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations
FR2758143B1 (fr) 1997-01-07 1999-02-19 Laphal Laboratoire De Pharmaco Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040018197A1 (en) 2002-04-26 2004-01-29 Promega Corporation Treatment for weight loss
EP1803714A1 (en) 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
US8258321B2 (en) * 2007-10-31 2012-09-04 Burnham Institute For Medical Research Beta-lactone compounds
CN106470804B (zh) 2014-06-30 2019-09-10 工机控股株式会社 电动工具
WO2017079299A1 (en) 2015-11-03 2017-05-11 Mayo Foundation For Medical Education And Research Using colipase inhibitors to treat pancreatitis
EP3651784B1 (en) 2017-07-12 2022-09-28 Mayo Foundation for Medical Education and Research Compounds for the reducing lipotoxic damage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523131A (ja) 2004-02-23 2007-08-16 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング リパーゼ抑制剤としてのアルキルカルバマート置換したβ−ラクトン
US20120289588A1 (en) 2011-04-15 2012-11-15 Vijay Prem Singh Lipase Inhibitors for the Treatment of Pancreatitis and Organ Failure
US20150099800A1 (en) 2012-05-24 2015-04-09 Northeastern University Novel lipase inhibitors, reporter substrates and uses thereof
WO2016102541A1 (en) 2014-12-22 2016-06-30 Université Libre de Bruxelles Composition comprising vancomycin and orlistat

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2008年，51(21)，P.6970-6979
Journal of the Chemical Society, Perkin Transactions 1，1998年，(8)，P.1373-1382

Also Published As

Publication number Publication date
WO2019014434A1 (en) 2019-01-17
ES2934883T3 (es) 2023-02-27
SG11202000239XA (en) 2020-02-27
AU2024278291A1 (en) 2025-01-09
US11976040B2 (en) 2024-05-07
CN111343999A (zh) 2020-06-26
RU2020105488A (ru) 2021-08-12
PL3651784T3 (pl) 2023-06-19
EP3651784B1 (en) 2022-09-28
EP4218753A2 (en) 2023-08-02
CA3069526A1 (en) 2019-01-17
US20210139421A1 (en) 2021-05-13
EP3651784A4 (en) 2021-05-05
JP2020527138A (ja) 2020-09-03
BR112020000635B1 (pt) 2023-04-18
US11339126B2 (en) 2022-05-24
IL271884B2 (en) 2023-07-01
KR102679975B1 (ko) 2024-06-28
IL271884A (en) 2020-02-27
AU2018300985A1 (en) 2020-01-30
AU2018300985B2 (en) 2024-09-12
EP3651784A1 (en) 2020-05-20
US20250340512A1 (en) 2025-11-06
US20220324797A1 (en) 2022-10-13
EP4218753B1 (en) 2025-12-03
BR112020000635A2 (pt) 2020-07-14
PL4218753T3 (pl) 2026-04-20
ES3064684T3 (en) 2026-04-28
DK4218753T3 (da) 2026-03-09
US12325690B2 (en) 2025-06-10
CN111343999B (zh) 2022-03-01
US20230250057A1 (en) 2023-08-10
US20240343688A1 (en) 2024-10-17
IL271884B1 (en) 2023-03-01
US11623915B2 (en) 2023-04-11
EP4218753A3 (en) 2023-10-11
RU2020105488A3 (enExample) 2021-08-27
KR20200027975A (ko) 2020-03-13

Similar Documents

Publication Publication Date Title
US12325690B2 (en) Compounds for the reducing lipotoxic damage
US8569536B2 (en) C-nitroso-derived nitroxyl donors
US11319292B2 (en) Metabolically stable 5-HMF derivatives for the treatment of hypoxia
US20220184032A1 (en) Indoline derivatives for treatment and/or prevention of fibrosis diseases
JP6563998B2 (ja) 治療計画
US8962687B2 (en) Method of treating liver disorders
RU2776343C2 (ru) Соединения для снижения липотоксического повреждения
HK40029799A (en) Compounds for the reducing lipotoxic damage
HK40029799B (en) Compounds for the reducing lipotoxic damage
JPWO1996006825A1 (ja) グアニジノメチルシクロヘキサンカルボン酸エステル誘導体
US12583834B2 (en) Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230207

R150 Certificate of patent or registration of utility model

Ref document number: 7224331

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250